Regenexx

What Regenexx does

Regenexx is a private regenerative medicine company founded in 2005 (with operational roots to 2003) by Chris Centeno, MD and headquartered in Broomfield, Colorado. It develops non-surgical orthopedic treatments using autologous bone marrow concentrate (BMC), platelet-rich plasma (PRP), and other orthobiologic injections delivered under image guidance (x-ray or ultrasound). Its proprietary lab processing claims 20x concentration of stem cell-containing bone marrow, and its patented Perc-ACLR procedure is a percutaneous ACL repair supported by published randomized controlled trial data. The company serves patients with osteoarthritis, joint injuries, spine pain, ligament tears (ACL, rotator cuff), and overuse conditions who are seeking alternatives to invasive orthopedic surgery.

Regenexx monetizes primarily through its licensed physician network of over 100 affiliated clinics in the United States plus international sites in Australia, Belgium, Cayman Islands, India, Puerto Rico, and Taiwan. Affiliated physicians operate as independent contractors licensing Regenexx intellectual property and protocols, and revenue to the parent entity flows through procedure-related licensing, supplies, telemedicine consultations, and ancillary products such as Regenexx Supplements. The direct-to-consumer go-to-market is supported by an extensive content marketing operation, including a large categorized blog, social media presence on Facebook/Instagram/Twitter/YouTube, patient testimonials and case studies, telemedicine evaluations, eBooks, webinars, and an online physician directory.

The company has 21+ years of clinical experience and thousands of documented patient outcomes, holds IOF (Interventional Orthobiologics Foundation) membership and BBB accreditation, and expanded via acquisition of Harbor View Medical in 2017. In 2024 Regenexx was sued by the FDA over allegedly inflated efficacy claims, which is a material regulatory and reputational overhang on its growth trajectory. No public funding rounds, revenue disclosures, or institutional investors are identified in the available data.

Name

Regenexx

Legal name

Regenexx

Website

https://regenexx.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Regenexx is a private regenerative medicine company operating a licensed physician network of 100+ US and international clinics that delivers non-surgical orthopedic treatments — including bone marrow concentrate, PRP, and Perc-ACLR procedures — to patients seeking alternatives to invasive surgery.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Interventional Orthobiologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Regenerative medicine procedures
• Orthopedic stem cell therapy
• Bone marrow concentrate treatments
• Platelet rich plasma injections
• Non-surgical orthopedic care

Headquarters

HQ city

Broomfield

HQ country

United States

HQ region

North America

Offices123 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Regenerative Medicine Procedures: Revenue generated from providing non-surgical orthopedic treatments using bone marrow concentrate (BMC), platelet-rich plasma (PRP), and other orthobiologic injections. Services are delivered through a network of licensed affiliated physicians at over 100 locations

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Regenexx provides non-surgical orthopedic treatments using autologous bone marrow concentrate (BMC), platelet-rich plasma (PRP), and other orthobiologic injections through a network of licensed physicians at over 100 locations in the U.S. and abroad. Treatments are delivered via patented protocols that achieve 20x stem cell concentration and image-guided injections to treat joint pain, osteoarthritis, ligament tears, and spinal conditions as an alternative to surgery.

Product overview

Regenexx is a regenerative medicine company offering non-surgical alternatives to orthopedic surgery through a network of licensed physicians. The core offering consists of proprietary bone marrow concentrate (BMC) procedures that achieve 20x concentration of stem cells, along with PRP injections and specialized procedures like the Perc-ACLR for ACL repair. The company operates over 100 clinic locations nationwide and international locations, providing same-day treatment for orthopedic conditions including knee, spine, shoulder, hip, hand/wrist, foot/ankle, and elbow issues. Additional offerings include supplements and telemedicine services. The approach uses board-certified doctors with expertise in image-guided injections and is supported by over 21 years of research and patient outcome data.

Differentiator

Problem solved

Functional benefit

Brands

• Perc-ACLR: A percutaneous ACL repair procedure using bone marrow concentrate to help heal torn ACLs without surgery.

Products and services

• Regenexx Procedures (Bone Marrow Concentrate & Orthobiologic Treatments) A suite of non-surgical orthopedic treatments using proprietary, research-based methods and patented protocols that prepare and precisely apply injectates (bone marrow concentrate, stem cells, PRP) to support the body's natural healing processes for joint pain, injuries, and osteoarthritis. Delivered through a network of licensed physicians at 100+ locations.
• Bone Marrow Concentrate (BMC) Procedures Proprietary bone marrow concentrate procedures that achieve 20x concentration of stem cell-containing bone marrow, using image-guided injections to treat orthopedic conditions (osteoarthritis, joint injuries, spine conditions) without surgery.
• Perc-ACLR Procedure A proprietary percutaneous ACL repair procedure using bone marrow concentrate and x-ray guidance to help patients heal torn ACLs without surgery. The company has published randomized controlled trial data on this procedure.
• Platelet-Rich Plasma (PRP) Injections Injections using concentrated platelets from the patient's own blood to promote healing in orthopedic injuries and conditions, delivered via image-guided techniques by Regenexx network physicians.
• Regenexx Supplements Nutritional supplements designed to support joint health and complement the regenerative treatment process for patients undergoing or recovering from Regenexx procedures.
• Regenexx Telemedicine Virtual consultation services allowing patients to receive expert evaluations and second opinions remotely from Regenexx physicians, supporting candidate screening for procedures.

Quantifiable outcome

• 20x stem cell concentration achieved through proprietary lab processing
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Others

• Organogenesis Holdings: Organogenesis is a regenerative medicine company focused on wound care and surgical biologics (skin, active wound care). It is thematically adjacent via regenerative biologics manufacturing and distribution but does not directly compete in interventional orthopedics.

Emerging players

• Mesoblast Limited: Mesoblast develops mesenchymal stem cell therapies (e.g., remestemcel-L, rexlemestrocel-L) targeted at orthopedic inflammation and disc disease. While still in regulatory/clinical stages, it targets the same regenerative-medicine-for-orthopedics category as Regenexx and represents a future therapeutic alternative.
• InGeneron: InGeneron develops point-of-care autologous regenerative cell therapy systems for orthopedic and wound-care applications. Competes in the same interventional orthobiologics category with a device-plus-procedure model aimed at orthopedic surgeons.
• Direct Biologics: Direct Biologics markets regenerative biologics (including a mesenchymal stem cell product) to orthopedic and pain specialists, often via clinic channels. It overlaps with Regenexx on orthobiologics supply and the same patient-degenerative-orthopedic segment.
• BioRestorative Therapies: BioRestorative Therapies develops autologous cell-based therapeutics for disc/spine and metabolic disease. Its BRTX-100 platform addresses intervertebral disc degeneration, overlapping with Regenexx's spine pain and disc-disease patient segment.

Broad incumbents

• Zimmer Biomet Holdings: Zimmer Biomet is one of the largest orthopedic device companies globally, with deep presence in joint reconstruction (knee, hip, shoulder) and sports medicine. Its surgical joint replacement portfolio is the dominant incumbent alternative to Regenexx's regenerative orthopedics positioning.
• Stryker Corporation: Stryker is a global orthopedic medical device leader spanning joint reconstruction, trauma, and sports medicine. Its core surgical-joint-replacement franchise is the incumbent alternative to Regenexx's non-surgical orthobiologics procedures, competing indirectly for the same orthopedic patient budgets.
• Smith+Nephew: Smith+Nephew is a global medical devices company with a sports medicine and orthobiologics portfolio (including cartilage repair and PRP adjuncts). It represents an incumbent orthobiologics-and-surgical alternative competing for the same patient decision point as Regenexx.

Direct peers

• Vericel Corporation: Vericel develops and commercializes autologous cell therapies for orthopedic sports medicine (e.g., MACI for cartilage repair), making it the most direct publicly-traded comparator to Regenexx's autologous bone-marrow-based orthopedic regenerative procedures. Both companies compete for the same patient pool seeking non-surgical orthopedic solutions.
• StemGenex Stem Cell Clinic Network: StemGenex operates a network of clinics offering autologous adult stem cell and PRP therapies for orthopedic and degenerative conditions. Mirrors Regenexx's franchise-style clinic-network model and direct-to-consumer cash-pay orthobiologics proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Regenexx
• YouTubeyoutube.com/user/Regenexx
• Facebookfacebook.com/Regenexx
• Instagraminstagram.com/regenexx

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenexx